Novo Nordisk Pharmatech has entered an agreement with IMCoPharma to distribute pharmaceutical grade quaternary ammonium compounds (Quats) to the healthcare industry in the Russian market and CIS countries.
Lukas Adamec, Commercial Director of IMCoPharma, commented on this new collaboration: “I am very happy for our collaboration with Novo Nordisk Pharmatech, which started already at the end of 2020 in several CIS countries. We are proud to be a partner of an experienced European company with exceptional healthcare products and represent their product portfolio among our customers across Eastern Europe and Middle Asian countries.”
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride, Cetyl Trimethyl Ammonium Bromide (CTAB) and Cetrimide) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standard – and Recombinant Insulin for use in cell culture media to enhance cell growth, viability, and productivity.
The products comply with the latest pharmacopoeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.
“For many years, we have been trying to find a strong partner for the Russian market who can also service CIS countries. And we are pleased that we now entered into a partnership with IMCoPharma, who will extend our very high standards and good distribution practice to the market mentioned above. We all look forward to a successful collaboration in the years to come,” says Gernot Stadlmann, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.